Abstract
Gene silencing associated with aberrant DNA methylation of promoter CpG islands is one mechanism through which tumor suppressor genes are inactivated in human cancers. TMS1 (target of methylation‐induced silencing) is a CpG island‐associated gene that functions in the regulation of apoptosis. In this study, we examined the DNA methylation status of the TMS1 promoter in ovarian cancer cell lines and tissues by methylation‐specific PCR (MSP) and its mRNA expression by reverse transcription and quantitative PCR. Aberrant methylation of TMS1 was present in 7/12 ovarian cancer cell lines and 8/20 primary ovarian cancer tissues. The median value of relative TMS1 gene expression in cancers with methylation (0.15) was significantly lower than that in cancers without methylation (13.9) (P<0.001). The expression of the TMS1 gene was relatively high (48.5) in the normal ovarian cDNA library. TMS1 gene expression was restored by treatment with the demethylating agent 5‐aza‐2′‐deoxycitidine in the OV90 cell line, which lacks the TMS1 transcript. Our results suggest that aberrant methylation of TMS1 may play a role in the pathogenesis of ovarian cancer. (Cancer Sci 2004; 95: 40–43)
References
- 1. Miki Y, Swensen J, Shattuck‐Eidens D, Futreal PA, Harshman K, Tartigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71. [DOI] [PubMed] [Google Scholar]
- 2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rices C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, , Deborah FordTonin P , Bishop DT, Spurr NK, Ponder Bruce AJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–92. [DOI] [PubMed] [Google Scholar]
- 3. Newman B, Millikan RC, King MC. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev 1997; 19: 69–79. [DOI] [PubMed] [Google Scholar]
- 4. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457–62. [PMC free article] [PubMed] [Google Scholar]
- 5. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription Trends Genet 1997; 13: 444–9. [DOI] [PubMed] [Google Scholar]
- 6. Razin A, Ceder H. DNA methylation and gene expression. Microbiol Rev 1991; 55: 451–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163–7. [DOI] [PubMed] [Google Scholar]
- 8. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225–9. [PubMed] [Google Scholar]
- 9. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation‐induced gene silencing in human breast cancers. Cancer Res 2000; 60: 6236–42. [PubMed] [Google Scholar]
- 10. Schmitt AO, Specht T, Beckmann G, Dahl E, Pilarsky CP, Hinzmann B, Rosenthal A. Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues. Nucleic Acids Res 1999; 27: 4251–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. McConnell BB, Vertino PM. Activation of a caspase‐9‐mediated apoptotic pathway by subcellular redistribution of the novel caspase recruitment domain protein TMS1. Cancer Res 2000; 60: 6243–7. [PubMed] [Google Scholar]
- 12. Levine JJ, Stimson‐Crider KM, Vertino PM. Effects of methylation on expression of TMS1/ASC in human breast cancer cells. Oncogene 2003; 22: 3475–88. [DOI] [PubMed] [Google Scholar]
- 13. Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, Tonk V, Padar A, Takahashi T, Roth JA, Euhus DM, Minna JD, Gazdar AF. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer. Int J Cancer 2003; 106: 198–204. [DOI] [PubMed] [Google Scholar]
- 14. Moriai R, Tsuji N, Kobayashi D, Yagihashi A, Namiki Y, Takahashi H, Watanabe N. A proapoptotic caspase recruitment domain protein gene, TMS1, is hypermethylated in human breast and gastric cancers. Anticancer Res 2002; 22: 4163–8. [PubMed] [Google Scholar]
- 15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation‐specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Stimson KM, Vertino PM. Methylation‐mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island‐localized changes in chromatin architecture. J Biol Chem 2002; 277: 4951–8. [DOI] [PubMed] [Google Scholar]
- 17. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–62. [DOI] [PubMed] [Google Scholar]
- 18. Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES. The PYRIN‐CARD protein ASC is an activating adaptor for caspase‐1. J Biol Chem 2002; 277: 21119–22. [DOI] [PubMed] [Google Scholar]
- 19. Wang L, Manji G, Grenier JM, Al‐Garawi A, Merriam S, Lora JM, Geddes BJ, Briskin M, DiStefano PS, Bertin J. PYPAF7, a novel PYRIN‐containing Apaf1‐like protein that regulates activation of NF‐kappa B and caspase‐1‐de‐pendent cytokine processing. J Biol Chem 2002; 277: 29874–80. [DOI] [PubMed] [Google Scholar]